Researchers from Mount Sinai School of Medicine have developed a new computational method that will help organize scientific data, making it easier for scientists to identify and prioritize genes, drug targets, and connections between drugs. By mining large datasets more simply and efficiently, researchers will be able to better understand gene-gene, protein-protein, and drug/side-effect interactions. The new algorithm is openly available, can be applied to any data and will also help scientists identify fellow researchers with whom they can collaborate.
Led by Avi Ma'ayan, PhD, Assistant Professor of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine, and Neil Clark, PhD a postdoctoral fellow in the Ma'ayan laboratory, the team of investigators used the new algorithm to create 15 different types of gene-gene networks. They also discovered novel connections between drugs and side effects, and built a collaboration network that connected Mount Sinai investigators based on their past publications.
"The algorithm makes it simple to build networks from data," said Dr. Ma'ayan. "Once high dimensional and complex data is converted to networks, we can understand the data better and discover new and significant relationships, and focus on the important features of the data."
The approach is presented in two separate publications in the journals BMC Bioinformatics and BMC Systems Biology. The tools that implement the approach Genes2FANs and Sets2Networks can be found online at http://actin.pharm.mssm.edu/genes2FANs and http://www.maayanlab.net/S2N.
In an example of how the tools work, the group analyzed one million medical records of patients to build a network that connects commonly co-prescribed drugs, commonly co-occurring side effects, and the relationships between side effects and combinations of drugs. They found many unreported side effects are caused by many drugs. They also looked at 53 cancer drugs and connected them to 32 severe side effects. When chemotherapy was combined with cancer drugs that work through cell signaling, there was a strong link to cardiovascular related adverse events. These findings can assist in post-marketing surveillance safety of approved drugs.
The Mount Sinai Medical Center